KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neck.

Atul Sharma, Manish Kumar Choudhary, Suman Bhasker, Akash Kumar, Alok Thakar, Raja Pramanik, Ahitagni Biswas, Kapil Sikka, Surya V S Deo, Ashok Kumar, Supriya Mallick, Amit Chirom Singh, Pooja Sethi, Amit Sehrawat, Vishnubhatla Sreenivas, Rajeev Kumar, Saphalata Baghmar, Aanchal Kakkar, Vinod Sharma, Babita Kataria, Ranjit Sahoo, Aman Sharma, Prasanth Ganesan, Sudhir Kumar, Amol Patel, Smriti Panda, Sanjay Thulkar, Sandeep Seth, Shikha Halder, Manoj Gupta, Ashish Dutt Upadhyay

J Natl Cancer Inst 118(11) 2178-2188

PMID42636269
PMCID-
DOI10.1093/jnci/djag276
发表日期2026-08-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: Concurrent chemoradiation therapy with cisplatin (100 mg/m² every 3 weeks) is the standard for locally advanced head and neck squamous cell carcinoma, but it is uncertain whether weekly cisplatin (40 mg/m²) is noninferior. METHODS: This open-label, multicenter, phase 3 noninferiority trial randomly assigned patients with non-nasopharyngeal locally advanced head and neck squamous cell carcinoma at a ratio of 1:1 to receive either the standard cisplatin regimen (100 mg/m² every 3 weeks) or the experimental weekly regimen (40 mg/m²), both with 70-Gy concurrent radiation. The primary endpoint was 2-year locoregional control, and the noninferiority margin was kept as 10% (-10%). RESULTS: From April 2018 to January 2021, 278 patients were enrolled (137 to the standard arm and 141 to the experimental arm); 272 were eligible for final analysis. Median follow-up was 43.9 months. Two-year locoregional control rates were 61.3% for the experimental arm and 51.1% for the standard arm, with an absolute difference of 10.2% (1-sided 95% CI lower bound = 0.30), which is within the noninferiority margin. The hazard ratio was 0.72 (95% CI = 0.50 to 1.05, P = .09). Kaplan-Meier analysis confirmed noninferiority (absolute difference = 10.8%). Median progression-free survival was 17.9 months (standard arm) and 20.3 months (experimental arm) (P = .20); median overall survival was 22.2 months (standard arm) and 24.9 months (experimental arm) (P = .50). Grade 3 or higher adverse events occurred more frequently in the standard arm (60.7% vs 44.7%, P = .01), as did hospitalizations (36.8% vs 20.3%, P = .004). CONCLUSION: Weekly low-dose cisplatin-based chemoradiation therapy is noninferior to high-dose cisplatin every 3 weeks and is associated with lower toxicity and fewer hospitalizations, making it a viable treatment option for non-nasopharyngeal locally advanced head and neck squamous cell carcinoma.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。